$PTHS
Channel Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Healthcare
Sector
Biotechnology
Industry
Francis Knuettel II,
CEO
4
Employees
$27.01
Current Price
$8.90M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $7,724.37 | 283 | ||
| 1 month | Buys | 1 | 2 | $999,983.28 | 35,948 | 129.46:1 |
| Sells | 1 | 2 | $7,724.37 | 283 | ||
| 2 months | Buys | 1 | 2 | $999,983.28 | 35,948 | 20.84:1 |
| Sells | 2 | 3 | $47,989.32 | 1,783 | ||
| 3 months | Buys | 1 | 2 | $999,983.28 | 35,948 | 10.78:1 |
| Sells | 4 | 9 | $92,769.16 | 3,924 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Jun 15, 2026 | Friedberg Ezra M Director | Sale | 59 | $27.94 | $1,648.48 | View Details |
| Jun 15, 2026 | Friedberg Ezra M Director | Sale | 224 | $27.12 | $6,075.89 | View Details |
| Jun 11, 2026 | Davis Todd C Director | Purchase | 503 | $28.73 | $14,449.23 | View Details |
| Jun 11, 2026 | Davis Todd C Director | Purchase | 35,445 | $27.80 | $985,534.05 | View Details |
| May 22, 2026 | Francis Knuettel II CFO, Treas & Secty | Sale | 1,500 | $26.84 | $40,264.95 | View Details |
| Apr 2, 2026 | Friedberg Ezra M Director | Sale | 265 | $21.36 | $5,660.72 | View Details |
| Apr 2, 2026 | Friedberg Ezra M Director | Sale | 293 | $20.51 | $6,010.05 | View Details |
| Apr 2, 2026 | Pauls Matthew Director | Sale | 415 | $20.52 | $8,513.89 | View Details |
| Apr 2, 2026 | Pauls Matthew Director | Sale | 371 | $21.36 | $7,925.60 | View Details |
| Apr 2, 2026 | Greenleaf Peter Director | Sale | 420 | $20.52 | $8,616.34 | View Details |
| Apr 2, 2026 | Greenleaf Peter Director | Sale | 377 | $21.36 | $8,053.25 | View Details |
4 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: